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Objectives: We examined the potential association
between prior chronic obstructive pulmonary disease
(COPD) and edentulism, and whether the association
varied by COPD severity using data from the Dental
Atherosclerosis Risk in Communities Study.
Design: Cross-sectional.
Setting: Community dwelling subjects from four US
communities.
Participants and measurements: Cases were
identified as edentulous (without teeth) and subjects
with one or more natural teeth were identified as dentate.
COPD cases were defined by spirometry measurements
that showed the ratio of forced expiratory volume (1 s) to
vital capacity to be less than 0.7. The severity of COPD
cases was also determined using a modified Global
Initiative for Chronic Obstructive Lung Disease
classification criteria (GOLD stage I–IV). Multiple logistic
regression was used to examine the association between
COPD and edentulism, while adjusting for age, gender,
centre/race, ethnicity, education level, income, diabetes,
hypertension, coronary heart disease and congestive
heart failure, body mass index, smoking, smokeless
tobacco use and alcohol consumption.
Results: 13 465 participants were included in this
analysis (2087 edentulous; 11 378 dentate).
Approximately 28.3% of edentulous participants had prior
COPD compared with 19.6% among dentate participants
(p<0.0001). After adjustment for potential confounders,
we observed a 1.3 (1.08 to 1.62) and 2.5 (1.68 to 3.63)
fold increased risk of edentulism among GOLD II and
GOLD III/IV COPD, respectively, as compared with the
non-COPD/dentate referent. Given the short period of time
between the measurements of COPD (visit 2) and dentate
status (visit 4) relative to the natural history of both
diseases, neither temporality nor insight as to the
directionality of the association can be ascertained.
Conclusions:We found a statistically significant
association between prior COPD and edentulism, with
evidence of a positive incremental effect seen with
increasing GOLD classification.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is currently the fifth leading cause
of death world-wide, and is expected to rise
to fourth place in 2030.1 Although COPD
has a heterogeneous clinical presentation
primarily characterised by airflow limitation,
generally associated with an abnormal
inflammatory response of the lungs,2 it is
also often associated with a significant sys-
temic inflammatory response3 which has




▪ We performed a cross-sectional analysis of a
community-dwelling population of 13 465 parti-
cipants enrolled in the Atherosclerosis Risk in
Communities (ARIC).
▪ We searched for a potential association between
edentulism and Global Initiative for Chronic
Obstructive Lung Disease (GOLD) scoring levels
for chronic obstructive pulmonary disease
(COPD).
▪ Multiple logistic regression models were used to
examine the association while adjusting for mul-
tiple covariates and confounders.
Key messages
▪ We found a statistically significant association
between edentulism (no teeth) and prior
obstructive airway disease in fully adjusted
models with incremental effects with increasing
GOLD classification.
▪ A similar association with periodontal disease
severity and COPD among those with teeth
(dentate) was also observed.
Strengths and limitations of this study
▪ This is a large representative population that
includes African Americans that has full periodontal
examination and respiratory function data.
▪ A GOLD stage was determined by standardised
lung function testing.
▪ A limitation arises from the minor temporal dis-
crepancy in the collection of the periodontal
examination data and the respiratory function
assessments.
Offenbacher S, Beck JD, Barros SP, et al. BMJ Open 2012;2:e001615. doi:10.1136/bmjopen-2012-001615 1
Open Access Research
Over the past decade there has been an increased
interest in the link between respiratory diseases and oral
infection. Higher levels of tooth-associated microorgan-
isms (plaque) and periodontal disease have been asso-
ciated with COPD.5–7 Recently, in a very comprehensive
oral microbiology study, high levels of diverse
microbes—including several implicated in COPD and
denture stomatitis—were identified on previously worn
dentures.8 Thus, both the teeth and the dentures are
non-desquamating oral surfaces that allow the oral
biofilm to emerge eliciting periodontal disease or
denture stomatitis, respectively. This raises the question
as to whether denture-associated microbes may contrib-
ute to COPD in a manner analogous to periodontal
organisms. Because oral infections and denture-based
sources of sepsis are both treatable and preventable, the
potential association of high microbial burden of oral
origin to COPD may represent modifiable risk factors
that may potentially improve respiratory-related morbid-
ity. It has been suggested by Garcia et al 7 that the
observed association between oral health and COPD
may be due to the aspiration of oral pathogens, or a
common underlying host susceptibility trait that places
individuals at risk for both conditions such as an exag-
gerated inflammatory response that is triggered by oral
microbes.
Although numerous studies have examined the associ-
ation between oral health and respiratory diseases in
dentate individuals, the published literature are scant
with respect to studies that have examined the associ-
ation between edentulism and COPD status/severity. We
undertook the current study to examine the potential
association between COPD and edentulism using data
from the Atherosclerosis Risk in Communities (ARIC)
Study. We hypothesised that edentulism would be asso-
ciated with a diagnosis of COPD and display a higher
prevalence with spirometry categories of more pro-
nounced COPD. These data include not only dentate
status and full-mouth periodontal examination measure-
ments, but also include results from direct pulmonary
function tests and symptomology assessments that
enabled classification of COPD severity.
METHODS
We sought to test the hypothesis that the prevalence of
edentulism was greater among individuals with a
reported history of lung disease (ie, COPD) and that the
association with edentulism varied by COPD severity as
determined by a modified Global Initiative for Chronic
Obstructive Lung disease (GOLD) criteria. Our second
hypothesis was that among dentate subjects there was a
difference in the prevalence of periodontal disease
according to the severity of COPD as measured by
GOLD criteria.
Study population and study design
The entire cohort from the ARIC study was 15 792 and
the available dental cohort Dental ARIC (D-ARIC) data
were used to study participants with both a periodontal
examination and completed spirometry data. The
cohort selection process and reasons for exclusion
appear in figure 1. Descriptions of the cohort and the
periodontal examination procedure have been
described previously.9 Eligible participants were all aged
45–64 at study entry (ie, visit 1) and had spirometry mea-
surements at visit 2 (3 years later) and periodontal exam-
inations at D-ARIC visit 4 (6 years from visit 2).
Case definitions
Edentulism case definitions were defined as study parti-
cipants without any natural teeth or implants.
Participants with one or more natural teeth (comprising
11 378 subjects) were selected as the dentate subjects.
The absence, presence or severity of periodontal disease
among dentate subjects was determined using the joint
American Association of Periodontology/Center for
Disease Control (AAP/CDC) consensus definitions of
Health, Early and Advanced disease.10
Figure 1 Participant flow
diagram.
2 Offenbacher S, Beck JD, Barros SP, et al. BMJ Open 2012;2:e001615. doi:10.1136/bmjopen-2012-001615
COPD and edentulism
This investigation represents the first report that uses
actual pulmonary function data to assess lung function
as an exposure related to edentulism or periodontal
disease. The measured exposure of pulmonary function
was classified both as a dichotomous (eg, COPD vs no
COPD) and ordinal categorical variable (eg, no lung
disease, restrictive disease, COPD GOLD stages I–IV),
using the following criteria.
Airway obstruction
Dichotomous variable (COPD/no COPD)—prior airway
obstruction (or COPD) was defined based on spirometry
measurements collected during visit 2. Participants with
a ratio of forced expiratory volume in 1 s (FEV1) and
forced vital capacity (FVC) less than 0.7 were deter-
mined to have airway obstruction consistent with COPD.
Ordinal categorical variable (COPD GOLD stage)—
severity of COPD was also examined in this study among
COPD participants using a modification of the
spirometry-based criteria for severity outlined in the
GOLD guidelines.11 12
GOLD stage Spirometry criteria
No lung
disease
FEV1/FVC≥0.7 and FEV1≥80% predicted
Restrictive
disease
FEV1/FVC≥0.7 and FVC<80% predicted
Stage 0 Presence of respiratory symptoms in the
absence of any lung function abnormality;
and no lung disease
Stage I FEV1/FVC<0.7 and FEV1≥80% predicted
Stage II FEV1/FVC<0.7 and 50%≤FEV1<80%
predicted
Stage III FEV1/FVC<0.7 and 30%≤FEV1<50%
predicted
Stage IV FEV1/FVC<0.7 and FEV1<30% predicted
Variables of interest
Smoking data (both for cigarettes and cigars) collected
during visit 4 were used to adjust for the confounding
effect of smoking on the relationship between airway
obstruction (COPD) and being edentulous. Smoking
was treated as a five-level categorical variable, as
described in detail previously.7 Cardiovascular disease
comorbidities that may be associated with both history of
airway obstruction and being edentulous were also
examined using data from visit 4. Other potential con-
founders examined included race and examination
centre, ethnicity, education level, income, frequency of
dental visits, diabetes, body mass index, alcohol use and
medication utilisation. These data were extracted from
visit 4.
Data analysis
Multivariable logistic regression was used to examine the
association between COPD and edentulous status. This
was followed by a logistic regression analysis of the
dentate subjects comparing the COPD prevalence and
severity of dentate patients without periodontal disease
to that of dentate patients with periodontal disease.
The exposure variable, which is airway obstruction, was
examined as both a dichotomous variable (eg, positive
prior COPD vs no COPD) and by logistic models using
nominal variables (eg, no lung disease, restrictive
disease, GOLD 0–IV) based on spirometry data collected
as part of the ARIC examination. For the no COPD or
GOLD reference group we included: subjects with and
without chronic respiratory symptoms with no lung func-
tion abnormality and subjects with GOLD 0 and restrict-
ive disease. Multiple regression models were used to
control for confounding. When adjusting for potential
confounding variables we included in certain models
variables that are known to modify either periodontal
disease status or COPD, including body mass index and
smokeless tobacco. We developed minimally and fully
adjusted logistical models incorporating significant con-
founders and effect modifiers to compute OR and 95%
CI using SAS V.9.2 (Cary, North Carolina, USA). We also
included traditional risk factors for edentulism, peri-
odontal disease and COPD–such as age, even if not stat-
istically significant in this cohort. A p value of <0.05 was
considered statistically significant for this study.
Sample size and power calculations
We knew a priori that the ARIC cohort who had spirom-
etry data from visit 2 included 2087 edentulous subjects,
as determined by questionnaire data at visit 4. We also
had 11 378 dentate subjects with spirometry data at
visit 2, of which 5155 subjects had a full-mouth peri-
odontal examinaton completed. Thus, if approximately
9% of the 13 465 subjects (2087 edentulous and 11 378
dentate) were determined to have COPD, we estimated
that we had >99% power to detect a significant differ-
ence of 1% at p=0.05 in the prevalence of COPD when
comparing edentulous versus dentate subjects.
RESULTS
ARIC subject participation was based upon the inception
cohort of 15 792 subjects. The visit 4 screenings were
broadly divided into 11 378 dentate and 2 087 edentu-
lous subjects who also had spirometry data. These sub-
jects are used for analyses in tables 1–6 on the
relationship between dentate status and COPD. Subjects
were excluded (n=2327) from the original inception par-
ticipants for incomplete data, dental implants only and
missing visit 4 screening.
The distribution of study subjects according to dentate
status and GOLD stage is shown in table 1. Among the
edentulous subjects (2087), there were 591 or 28.3%
with COPD (GOLD stages I–IV). With the exception of
GOLD I where the prevalence of edentulism was 14.7%,
the prevalence of edentulous individuals increased from
16.4% for GOLD 0 to 35.6% for GOLD III/IV. The
crude OR (not shown in table 1) for edentulism being
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associated with prior COPD versus no COPD was 1.62
(95% CI 1.46 to 1.80). Approximately 13% of individuals
with no chronic respiratory symptoms and no lung func-
tion abnormality (ie, no lung disease) were edentulous.
There were 2232 subjects with prior COPD (19.6%)
among 11 378 dentate subjects.
Table 2 presents the prevalence of various subject
characteristics according to GOLD classification. In this
Table 2 Demographics by GOLD stage
GOLD reference* GOLD I GOLD II GOLD III/IV p Value†
Edentulous 1496 (14.1%) 208 (14.7%) 290 (25.2%) 93 (35.6%)
Dentate 9146 (85.9%) 1204 (85.3%) 860 (74.8%) 168 (64.4%) <0.0001
Race/centre
MS African Americans 2654 (25.1%) 191 (13.6%) 196 (17.1%) 73 (28.4%)
NC African Americans 285 (2.7%) 35 (2.5%) 27 (2.4%) 11 (4.3%)
NC white 2211 (20.9%) 401 (28.5%) 344 (30.0%) 84 (32.7%)
Washington Co, MD 2680 (25.3%) 350 (24.9%) 337 (29.4%) 56 (21.8%)
Surburban minneapolis 2747 (26.0%) 430 (30.6%) 243 (21.2%) 33 (12.8%) <0.0001
Female 6344 (59.6%) 684 (48.4%) 457 (39.7%) 125 (47.9%)
Male 4298 (40.4%) 728 (51.6%) 693 (60.3%) 136 (52.1%) <0.0001
Mean age (SD) 62.4 (5.59) 64.2 (5.69) 64.9 (5.57) 64.2 (5.70) <0.0001
Mean BMI (SD) 29.2 (5.68) 27.1 (4.81) 27.6 (5.34) 27.3 (6.16) <0.0001
Diabetes (yes) 1573 (17.4%) 132 (10.8%) 179 (19.7%) 36 (20.7%)
No 7486 (82.6%) 1090 (89.2%) 732 (80.4%) 138 (79.3%) <0.0001
Hypertension (yes) 3591 (39.4%) 388 (31.9%) 374 (40.7%) 74 (41.8%)
No 5535 (60.7%) 829 (68.1%) 545 (59.3%) 103 (58.2%) <0.0001
Income (low) 2718 (31.1%) 365 (31.2%) 321 (37.2%) 72 (41.6%)
Medium 3071 (35.2%) 440 (37.6%) 316 (36.7%) 59 (34.1%)
High 2945 (33.7%) 366 (31.3%) 225 (26.1%) 42 (24.3%) <0.0001
Education (basic) 2226 (21.0%) 291 (20.6%) 332 (28.9%) 93 (35.8%)
Intermediate 4360 (41.0%) 564 (40.0%) 480 (41.8%) 101 (38.9%)
Advanced 4038 (38.0%) 556 (39.4%) 336 (29.3%) 66 (25.4%) <0.0001
Alcohol use (yes) 4404 (48.4%) 657 (53.9%) 463 (51.1%) 78 (44.3%)
No 4695 (51.6%) 561 (46.1%) 444 (49.0%) 98 (55.7%) 0.001
Smoke (current, heavy) 748 (8.6%) 191 (16.4%) 256 (29.8%) 33 (20.6%)
Current, light 245 (2.8%) 34 (2.9%) 15 (1.7%) 1 (0.6%)
Former, heavy 1304 (14.9%) 309 (26.5%) 339 (39.4%) 76 (47.5%)
Former, light 1981 (22.7%) 228 (19.6%) 100 (11.6%) 17 (10.6%)
Never 4448 (51.0%) 403 (34.6%) 150 (17.4%) 33 (20.6%) <0.0001
Smokeless tobacco (yes) 699 (7.7%) 131 (10.8%) 138 (15.2%) 34 (19.3%)
No 8401 (92.3%) 1088 (89.3%) 769 (84.8%) 142 (80.7%) <0.0001
Coronary heart disease (yes) 718 (6.9%) 106 (7.6%) 159 (14.2%) 31 (13.0%)
No 9727 (93.1%) 1281 (92.4%) 963 (85.8%) 208 (87.0%) <0.0001
Congestive heart failure (yes) 191 (2.1%) 25 (2.1%) 41 (4.6%) 9 (5.1%)
No 8878 (97.9%) 1194 (98.0%) 861 (95.5%) 166 (94.9%) <0.0001
*GOLD reference: no chronic respiratory symptoms and no lung function abnormality+GOLD zero (chronic respiratory symptoms and no lung
function abnormality)+restrictive (FEV1/FVC >= 0.70 and FVC<80% predicted).
†χ2 or t test.
BMI, body mass index; FEV, forced expiratory volume; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung
Disease.















abnormality) GOLD I GOLD II GOLD III/IV p Value*
Edentulous 1294 (13.3%) 151 (24.6%) 51 (16.4%) 208 (14.7%) 290 (25.2%) 93 (35.6%)
Dentate 8422 (86.7%) 464 (75.5%) 260 (83.6%) 1204 (85.3%) 860 (74.8%) 168 (64.4%) <0.0001
*χ2 test.
FEV, forced expiratory volume; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
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table, the GOLD reference group for statistical testing
combines the following three categories of subjects: no
lung disease, GOLD 0 and subjects with chronic respira-
tory symptoms but no lung function abnormality. The
general patterns reflected in table 2 show that compared
with the reference group those subjects in the GOLD III
and IV category were much more likely to be edentu-
lous, to smoke, to use smokeless tobacco, to be African
American or North Carolina Caucasians, men and some-
what more likely to have lower levels of income and edu-
cation, and to be older and more likely to have chronic
heart failure and heart disease.
Table 3 presents multivariable logistic models for the
relationship between edentulous/dentate status and
GOLD stages using the GOLD reference group
described above. In an unadjusted model individuals
with GOLD II and III/IV scores were at significantly
higher odds for edentulism that increased with increas-
ing GOLD stage severity (OR=2.06; 95% CI 1.79 to 2.38
and OR=3.38; 95% CI 2.61 to 4.39, respectively).
Minimally adjusted models (race/centre, sex and age)
showed similar significant effects for GOLD II and III/
IV with little attenuation. The increased risks of being
edentulous for GOLD II and III/IV categories remain
significant, but have slightly lower ORs. However, the
fully adjusted model showed more attenuation with the
odds for being edentulous being 1.3 (1.08 to 1.62) and
2.5 (1.68 to 3.63) times greater for GOLD II disease and
the most severe category GOLD III/IV, respectively.
Table 4 shows the association between periodontal
status and GOLD classifications for the dentate subjects.
Because of small cell sizes in the GOLD III and IV
groups, we combined them with GOLD II. Using the
CDC/AAP classification of periodontal disease, which is
based upon clusters of clinical signs, there is a signifi-
cant positive association between higher GOLD stage
and severe periodontal disease (p<0.0001). Subjects with
GOLD I or GOLD II–IV were more likely to have severe
periodontitis than the reference group. With respect to
the individual periodontal variables measured as means
Table 4 Periodontal measures among the 5155 dentate subjects by GOLD stages
GOLD reference* GOLD I GOLD II/III/IV Overall p Value
CDC/AAP definition
Healthy N (SD) 2378 (43.0%) 281 (38.1%) 151 (28.5%)
Entry N (SD) 2271 (41.1%) 295 (40.0%) 233 (44.1%)
Severe N (SD) 878 (15.9%) 161 (21.9%) 145 (27.4%) <0.0001
Mean (SD)
Extent PD >= 4 mm 7.05 (11.3) 8.12 (12.3)* 9.66 (14.8)**** <0.0001
Mean PD 1.89 (0.56) 1.94 (0.61) 2.03 (0.74)**** <0.0001
Extent AL >= 3 mm 21.7 (21.8) 27.6 (26.0)**** 34.3 (28.7)**** <0.0001
Mean AL 1.72 (0.96) 1.94 (1.15)**** 2.29 (1.43)**** <0.0001
Extent BOP 25.2 (23.4) 25.1 (24.3) 27.7 (26.4)** 0.07
Extent PQ >= 1 42.5 (38.3) 39.3 (37.7)* 49.9 (39.3)**** <0.0001





All p values are compared to reference group by χ2 or generalised logistic model.
AAP, American Association of Periodontology; AL, attachment loss relative to cemento-enamel junction; BOP, bleeding upon probing in % of
sites; CDC, Center for Disease Control; GOLD, Global Initiative for Chronic Obstructive Lung Disease; PD, probing depth in mm; PQ, plaque
index.
Table 3 Generalised logistic models: association between edentulism and GOLD stages as compared to dentate subjects
GOLD reference* GOLD I GOLD II GOLD III/IV
Model 1 crude
Edentulous Reference 1.06 (0.90 to 1.24) 2.06 (1.79 to 2.38) 3.38 (2.61 to 4.39)
Model 2 minimally adjusted†
Edentulous Reference 1.12 (0.93 to 1.34) 1.92 (1.61 to 2.28) 3.17 (2.28 to 4.41)
Model 3 fully adjusted‡
Edentulous Reference 1.05 (0.86 to 1.28) 1.32 (1.08 to 1.62) 2.47 (1.68 to 3.63)
*GOLD reference: no chronic respiratory symptoms and no lung function abnormality+GOLD zero (chronic respiratory symptoms and no lung
function abnormality)+restrictive (FEV1/FVC >= 0.70 and FVC<80% predicted).
†Model 2 is minimally adjusted for race/centre (5-level), male and age (years).
‡Model 3 is fully adjusted for race/centre (5-level), male, age (years), diabetes, hypertension, smoking (5-levels), smokeless tobacco, alcohol,
income (3-level), education (3-level), congestive heart failure and congestive heart disease.
FEV, forced expiratory volume; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
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or extent scores, individuals with a GOLD stage I were
more likely to have a greater extent of periodontal
pocket depths of 4 mm or more, greater extent of
attachment loss of 3 mm or more, a higher mean attach-
ment loss and a greater extent of plaque in their
mouths than the reference group. Those with GOLD
scores of II–IV were significantly higher on all periodon-
tal measures and had fewer teeth compared with the ref-
erence group.
Logistic models for the association between GOLD
stage and periodontal status using the AAP/CDC defini-
tions appear in table 5. As in table 4, small cell size
resulted in grouping the more severe GOLD stages
together as GOLD II/III/IV. In general, the ORs for
severe periodontal disease increased with more severe
GOLD stage in the crude, minimally adjusted and fully
adjusted models. There is also an increase in odds as the
severity of periodontal disease increases for the two
GOLD categories shown using the periodontally healthy
group as the reference group within each GOLD cat-
egory. Although adjusting for relevant confounders gen-
erally decreased the odds, there was still a statistically
significant association between higher GOLD stage and
severe periodontal disease in the fully adjusted model
(OR=1.41; 95% CI 1.07 to 1.87).
The relationship between spirometry-based GOLD
classification and self-reported physician-based diagnosis
of bronchitis or emphysema is shown in table 6.
Participants classified as GOLD III/IV were significantly
more likely to have self-reported bronchitis or emphy-
sema. There is a trend for a positive association except
for the GOLD zero category. Interestingly, 65.9% of sub-
jects with GOLD III/IV report no diagnosis of COPD
suggesting that self-report of bronchitis or emphysema is
not a strong predictor of GOLD stage. In fact, of all sub-
jects reporting a positive diagnosis of bronchitis or
emphysema 53% demonstrated no evidence of chronic
respiratory symptoms and no lung function abnormality.
DISCUSSION
We found a statistically significant association between
prior COPD and edentulism, with evidence of an
increasing prevalence of edentulism with increasing
GOLD stage. Although there was some reduction in the
magnitude of effect in the adjusted models, the associ-
ation between dentate status and GOLD stage remained
statistically significant even in the fully adjusted model,
with a 1.3-fold increased odds of being edentulous in
the GOLD II category and a 2.5-fold increased odds of
being edentulous in the most severe GOLD III/IV cat-
egory in the fully adjusted regression model. This repre-
sents the first report of an association between
edentulism and COPD in a population with spirometry
measurements.
In the subgroup of dentate subjects, there was a sig-
nificant association between the GOLD II–IV group
versus the GOLD reference group and prevalent periodon-
tal disease with a statistically significant increase in the odds
of entry level and severe periodontal disease in the crude
and minimally adjusted models. In the fully adjusted
model, only the association between GOLD II/III/IV and




















633 (6.5%) 65 (20.9%) 64 (10.4%) 143 (10.1%) 201 (17.5%) 89 (34.1%)
No 9083 (93.5%) 246 (79.1%) 551 (89.6%) 1269 (89.7%) 949 (82.5%) 172 (65.9%) <0.0001
*χ2 test.
FEV, forced expiratory volume; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Table 5 Generalised logistic models: periodontal status
(CDC/AAP definition) by GOLD stages
GOLD I GOLD II/III/IV
Model 1 crude
Healthy Reference Reference
Entry 1.10 (0.92 to 1.31) 1.62 (1.31 to 2.00)
Severe 1.55 (1.26 to 1.91) 2.60 (2.05 to 3.31)
Model 2 minimally adjusted*
Healthy Reference Reference
Entry 0.99 (0.83 to 1.19) 1.42 (1.14 to 1.77)
Severe 1.46 (1.17 to 1.82) 2.17 (1.67 to 2.80)
Model 3 fully adjusted†
Healthy Reference Reference
Entry 0.95 (0.79 to 1.14) 1.10 (0.87 to 1.39)
Severe 1.23 (0.97 to 1.55) 1.41 (1.07 to 1.87)
*Model 2 is minimally adjusted for race/centre (5-level), male and
age (years).
†Model 3 is fully adjusted for race/centre (5-level), male, age
(years), diabetes, hypertension, smoking (5-levels), smokeless
tobacco, alcohol, income (3-level) and education (3-level).
AAP, American Association of Periodontology, CDC, Center for
Disease Control; GOLD, Global Initiative for Chronic Obstructive
Lung Disease.
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severe periodontal disease (OR 1.41 (95% CI 1.07 to 1.87))
remained statistically significant. This is the first population
report to include both full-mouth periodontal examination
data as well as spirometry assessments, thereby providing
direct confirmation of the association between severe peri-
odontal disease and COPD, as well as a dose–response rela-
tionship between these conditions.
While there is no previous published information
available about the association between edentulism
status and COPD, there is evidence in the literature of
an association between periodontal disease and COPD,
consistent with the findings of the current study.5–7 The
results of this investigation were based on standardised
pulmonary function tests and suggest that studies that
are based upon self-reported diagnoses can potentially
result in statistically significant misclassification error.
Our data shown in table 6 suggest that of the 12 297 sub-
jects reporting no diagnosis, 2390 subjects or 19.4%
were classified as GOLD I–IV. Among those 433 subjects
with GOLD I–IV the positive predictive rate was only
15.3%. These findings suggest that an important
strength of the current study was the classification of
disease based on an objective biological measure (eg,
spirometry) rather than a self-reported measure.
Additional strengths of the current study include the
large sample size, the inclusion of African Americans
providing some racial diversity of the sample, the use of
a full-mouth examination protocol and the collection of
information about key confounding variables, including
but not limited to: tobacco use, hypertension, diabetes
and income. Furthermore, the outcomes of interest,
edentulism and periodontal disease, were evaluated
using a comprehensive oral examination at visit 4.
The current study must also be considered in light of
certain limitations. First, the design of the current study
does not allow us to determine the directionality or tem-
porality of any association found. It has been reported
previously that the dental ARIC subsample is healthier
than the greater ARIC sample and that the edentulous
subjects within the ARIC dataset have overall poorer
health,9 as compared with the ARIC dental sample.
Thus, it is possible that the observed relationship
between both edentulism and periodontal disease with
prior COPD may be due in part to shared risk factors.
There is also the potential bias due to differential loss to
follow-up prior to visit 4. The current study included
only those subjects with dental history information at
visit 4. Finally, it is possible that participants with COPD
may have been more likely to be lost to follow-up (com-
pared with participants without COPD) or that partici-
pants with more severe COPD may have had a lower
probability of surviving to visit 4 than participants with
mild COPD or normal lung function. There are no data
in this report to mechanistically link edentulism with
increased risk for COPD. Previous studies of periodontal
disease associations with COPD have discussed the
potential role of periodontal infection serving as a
chronic repository of pathogenic oral organisms that
could be aspirated into the airway to challenge the
lungs.6 Periodontal infections are also associated with
increases in systemic markers of inflammation including
biomarkers such as C reactive protein.13 By analogy,
edentulism is commonly associated with denture infec-
tions (denture mucositis) which induce mucosal inflam-
mation and unclean dentures can also pose as a chronic
reservoir of oral pathogens. However, the potential role
of denture-based infection as a potential risk factor for
COPD remains to be elucidated.
CONCLUSIONS
Edentulism was associated with prior COPD, with an
incremental effect observed with increasing GOLD
stage. Additionally, among dentate individuals, severe
periodontal disease was associated with GOLD classifica-
tion. This is one of the first analyses of COPD and
dentate status, and expands upon the available literature
regarding periodontal disease and COPD. Further
research is warranted to explore the relationship of
edentulism and periodontal disease with COPD.
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